GENETIC TESTING For Macular Degeneration
Genetic testing has been used in
medicine for several years. In 2009 a new genetic
test was introduced that can predict how a patient
with macular degeneration will progress. The
company’s name is Arctic Diagnostics Inc. Mr. Greg Hines is the
president and CEO. Previous genetic testing for
macular degeneration tested for those patients who
would develop late-state disease only. This newer
test for those diagnosed already with ARMD covers
the genotype spectrum for those who are at a low
risk for vision loss in the future as well as those
that have a medium or high risk for severe vision
The test involves using a cotton swab on the inside of the patient’s cheek with a gentle brush. The swab is air dried and sent to the genetic company for processing. Many insurance companies including Medicare now cover the new genetic test which is called Macular Risk. Who needs this testing? They are people who have been recently diagnosed with dry ARMD. The second group of concerned people would be relatives close to a person with a diagnosis of macular degeneration.
What purpose does it serve to know what the future may bring? Those found to be at low risk for developing vision loss will be relieved. Those other patients with a high risk for losing vision may have time to alter or change their lifestyles if they are considered harmful to their health.
In addition to lifestyle changes an internal nutritional analysis based on blood work can pinpoint body organ deficiencies which may be detrimental. See nutritional analysis page by clicking here. Also microcurrent therapy can be started with electrode pads over the eyes. This helps primarily dry macular degeneration patients which is the beginning stage for everyone diagnosed. This genetic test is considered to be 80% accurate and is much more reliable than previous genetic testing. There are four genes which are tested. They are CFH, C, ARMS 2 and the mitochondrial gene ND 2.10 This test is not for a healthy individual with 20/20 vision unless they have relatives that have been diagnosed.
The macular risk genetic test will tell you how your risk compares to the general population. The average Caucasian has a 9.8% risk of developing ARMD. The Arctic Diagnostic test will uncover 4 out 5 people destined to get the condition. Most people want to know if they are at risk only if something can be done about it. This is where microcurrent stimulation, oxygen inhalation, and nutritional support can be used as a combined therapy prior to losing vision.
See MCS (how does it work)
Brent Zanke, MD, PhD, FRCPC: Steven Hawken ,MSc;
Ronald Carter, (PHD; David Chow, MD, FRCSC – A
Genetic approach to stratification of risk for
age-related macular degeneration – Can J Ophthalmol